MaineCare covers GLP-1 medications such as Ozempic, Rybelsus, and Wegovy when they are prescribed for Type 2 diabetes or, in narrow circumstances, to reduce cardiovascular risk or treat advanced liver disease. It does not cover any GLP-1 prescribed solely for weight loss. A 2025 bill that would have added weight-loss coverage failed in committee, and as of mid-2026 no state law requires MaineCare to reimburse these drugs for obesity.
Which GLP-1 Drugs MaineCare Pays For
Rybelsus, the oral form of semaglutide, sits on the MaineCare Preferred Drug List as a preferred drug, so it can generally be dispensed without prior authorization when prescribed for a covered use.1MaineCare PDL. Pharmacy Unit Update – January 2025 PDL Changes
Wegovy, the injectable form of semaglutide, is non-preferred and carries tight clinical criteria. It can be authorized to reduce the risk of major adverse cardiovascular events in adults with a BMI above 27 who have a documented history of stroke, heart attack, or symptomatic peripheral arterial disease, and who are already taking a lipid-lowering medication. A separate pathway allows approval for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis, confirmed by biopsy or non-invasive testing and prescribed by a specialist.2MaineCare PDL. Semaglutide Prior Authorization Form
The prior authorization form for semaglutide asks directly whether the drug is being used for weight loss and states that “MaineCare policy does not allow coverage for weight loss products.”2MaineCare PDL. Semaglutide Prior Authorization Form The exclusion is longstanding. A 2017 review of Maine’s Medicaid obesity coverage documented that MaineCare had already carved anorectics and weight-loss drugs out of its Preferred Drug List.3GW Stop Obesity Alliance. Medicaid Obesity Coverage – Maine
One boundary worth naming: bariatric surgery is treated differently. MaineCare may cover it with prior authorization when the procedure is deemed medically necessary to treat a related condition such as diabetes or hypertension.3GW Stop Obesity Alliance. Medicaid Obesity Coverage – Maine So the exclusion is specific to weight-loss drugs, not obesity treatment in general.
Getting Approval for a Covered Indication
What the process looks like depends on where the drug sits on the Preferred Drug List. Rybelsus, as a preferred drug, generally does not require prior authorization. Wegovy does. The prescribing provider submits a request documenting the diagnosis, BMI, relevant medical history, and current medications.4Maine DHHS. MaineCare Covered Services and Benefits2MaineCare PDL. Semaglutide Prior Authorization Form
Initial approvals for semaglutide under the cardiovascular criteria are limited to three months.2MaineCare PDL. Semaglutide Prior Authorization Form You and your provider will each receive a letter with the decision. Medication questions can go to the Pharmacy Help Desk at 1-866-796-2463 or the Optum Helpdesk at 1-888-420-9711.1MaineCare PDL. Pharmacy Unit Update – January 2025 PDL Changes
If coverage is denied, you can request a fair hearing. The appeal must be filed within 30 days of the denial date. Requests go to a regional DHHS office by email, by phone at 1-855-797-4357, or by mail to the Commissioner of the Department of Health and Human Services at 11 State House Station, Augusta, ME 04333. The nonprofit Consumers for Affordable Health Care runs a HelpLine at 1-800-965-7476 that can walk you through the process.5Consumers for Affordable Health Care. How Can I Appeal a MaineCare Denial
Why Weight Loss Is Excluded
The exclusion traces back to federal law. Under the Medicaid Drug Rebate Program, states must cover almost every FDA-approved outpatient drug, but a statutory exception lets them leave out drugs used for weight loss. That makes obesity coverage of GLP-1s optional for every state Medicaid program in the country. As of January 2026, only 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service, and several that once offered coverage have pulled back on cost.6KFF. Medicaid Coverage of and Spending on GLP-1s
Cost drives the debate in Maine. Nationally, Medicaid gross spending on GLP-1 medications climbed from about $1 billion in 2019 to nearly $9 billion in 2024, with the average gross cost per prescription running near $1,000.6KFF. Medicaid Coverage of and Spending on GLP-1s Medicaid already accounts for close to a quarter of Maine’s General Fund spending, and testimony from the Maine Policy Institute during the 2025 legislative session warned that adding weight-loss coverage at roughly $1,000 per patient per month could produce runaway expenditures, given that the medications often require long-term or indefinite use.7Maine State Legislature. Testimony on LD 480 – Maine Policy Institute
The 2025 Bill That Would Have Changed This
LD 480, “An Act to Support Healthy Weight by Providing MaineCare Coverage for Certain Weight Loss Medications,” was introduced on February 6, 2025, by Representative Anne Graham with five Democratic co-sponsors. It would have required the Department of Health and Human Services to reimburse FDA-approved GLP-1 receptor agonists prescribed for obesity, with prior authorization and a limit that prescriptions come from a primary care provider or a bariatric specialist.8BillTrack50. Maine LD 480
The Health and Human Services Committee reported it “Ought Not to Pass” on March 20, 2025, and the bill was placed in legislative files, killing it for the session.9Maine Legislature. LD 480 Legislative Summary
A separate 2025 bill, LD 627, would have required commercial health insurers in Maine’s fully-insured market to cover GLP-1s for weight loss. That bill also died in April 2025.10Maine Legislature. LD 627 Legislative Summary It’s worth flagging only because searchers sometimes conflate the two: LD 627 targeted private insurance, not MaineCare, so its outcome does not affect Medicaid coverage in the state.
What Could Change MaineCare’s Position
Two federal developments could reshape the math without any new state law.
Lower Negotiated Prices
In November 2025, the Trump administration announced agreements with Eli Lilly and Novo Nordisk to offer “Most Favored Nation” pricing on injectable GLP-1 medications to every state Medicaid program. Under the deals, Ozempic, Mounjaro, Wegovy, and Zepbound would be available at $245 per month for all covered doses, well below list prices above $1,000.11AMCP. Federal Update – Trump Administration Announces Deal to Bring Most Favored Nation Pricing to GLP-1s Access to the $245 price for Medicaid programs is projected to begin in May 2026.12NCPA. About Trump Eli Lilly Novo Nordisk Deals GLP-1 Prices These prices are voluntary supplemental rebates negotiated separately from the standard Medicaid rebate program, and questions remain about how they interact with existing rebate structures.
The BALANCE Model
In December 2025, the CMS Innovation Center rolled out the BALANCE model (Better Approaches to Lifestyle and Nutrition for Comprehensive Health), a voluntary five-year initiative meant to negotiate lower GLP-1 prices and standardize coverage criteria across participating state Medicaid programs. State agencies became eligible to join beginning in May 2026.13CMS. BALANCE Model CMS has not yet published a participant list, and terms are still being finalized.14Kentucky Legislative Research Commission. Eli Lilly BALANCE Model Presentation Whether Maine has opted in is not publicly confirmed.
The National Trend Is Cautious
Even with cheaper drugs on the horizon, states are moving carefully. California, New Hampshire, Pennsylvania, and South Carolina recently dropped Medicaid coverage of GLP-1s for obesity because of budget pressure. North Carolina cut coverage in October 2025 during a budget stalemate and restored it in December 2025.6KFF. Medicaid Coverage of and Spending on GLP-1s15NC DHHS. NC Medicaid Reinstitute Coverage GLP-1s Weight Management The National Association of Medicaid Directors has opposed a proposed federal rule that would force state coverage of anti-obesity medications, citing annual cost projections of $30 million to $79 million for small states and $50 million to $126 million for medium-sized states.16National Association of Medicaid Directors. Optional Not Mandatory – NAMDs Recommendations on Anti-Obesity Medication Coverage The administration has not finalized that mandate, relying instead on the voluntary BALANCE model and the manufacturer deals.
For now, if you’re on MaineCare and want a GLP-1 for weight management alone, the request will be denied. If you have Type 2 diabetes, established cardiovascular disease with the specific criteria above, or qualifying MASH, the path exists through your prescriber and, when needed, the appeal process.